| 2026-09-01 | 8-K | Form 8-K, Item 1.02 |
| 2026-08-28 | 8-K | Form 8-K, Item 5.07 |
| 2026-08-19 | 8-K | Form 8-K, Item 8.01 |
| 2026-08-14 | 8-K | Form 8-K, Item 8.01 |
| Transcript | Q4 FY25 earnings call transcript |
| 2026-08-03 | Press release | Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update |
| 2026-08-03 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-03 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-10 | 8-K | Form 8-K, Item 1.01 |
| 2026-07-06 | Press release | Vertex to Acquire Crinetics Pharmaceuticals |
| 2026-07-06 | 8-K | Form 8-K, Item 1.01 |
| 2026-06-30 | Press release | Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026 |
| 2026-06-30 | Press release | Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026 |
| 2026-06-22 | 8-K | Form 8-K, Item 5.07 |
| 2026-06-14 | Press release | Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromega |
| 2026-06-14 | Press release | Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Present |
| 2026-06-14 | Press release | Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromega |
| 2026-06-14 | Press release | Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Present |
| 2026-06-02 | Press release | Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations |
| 2026-06-02 | Press release | Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Co |
| 2026-06-02 | Press release | Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations |
| 2026-05-22 | Press release | Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026 |
| 2026-05-22 | Press release | Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026 |
| 2026-05-07 | Press release | Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update |
| 2026-05-07 | Press release | Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update |
| 2026-05-07 | Deck | Presentation of Q1 2026 |
| 2026-05-07 | Press release | Press Release of Q1 2026 |
| 2026-05-07 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-07 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-07 | Transcript | Q1 FY26 earnings call transcript |
| 2026-04-29 | Proxy | Definitive proxy statement |
| 2026-04-27 | Press release | Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Ac |
| 2026-04-27 | Press release | Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Ac |
| 2026-04-10 | 8-K | Form 8-K, Item 5.02 |
| 2026-04-08 | Press release | Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 |
| 2026-04-08 | Press release | Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 |
| 2026-03-26 | Press release | Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusot |
| 2026-03-23 | 8-K | Form 8-K, Item 5.02 |
| 2026-03-03 | 8-K | Form 8-K, Item 4.01 |
| 2026-03-01 | Deck | Crinetics to Participate in TD Cowen 46 Annual Health Care Conference |